The present study is the first report demonstrating the significant association between TYMS genetic polymorphism, specifically TYMS rs11280056, and neurotoxicity among pancreatic cancer patients treated with FOLFIRINOX. This evidence concerns the gene TYMS and familial pancreatic carcinoma.